DLBCL: Real-World Use of Frontline Polatuzumab Vedotin Following the POLARIX Trial
August 31st 2023Following their discussion on the phase 3 POLARIX trial in DLBCL, Jonathan Friedberg, MD, MMSc, and the Oncology Brothers consider how frontline polatuzumab vedotin will be used in the real-world setting.